XHE - ETF AI Analysis
Top Page
SPDR S&P Health Care Equipment ETF (XHE)
XHE, the SPDR S&P Health Care Equipment ETF, has a solid overall rating that reflects a portfolio led by strong companies like Intuitive Surgical and Idexx Laboratories, which show robust financial performance and positive earnings call sentiment. Other key holdings such as Resmed, Stryker, and GE Healthcare also support the fund’s quality through strong growth and strategic initiatives, though common issues like high valuations, leverage, and some technical caution signals introduce risk. The main risk factor is that many top holdings share similar challenges—especially premium valuations and occasional technical or liquidity concerns—which can increase volatility if market sentiment toward the health care equipment sector turns negative.
XHE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 151.14M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.80
- Issuer
- SPDR
- Inception Date
- Jan 26, 2011
- Dividend Yield
- 0.08%
- Asset Class
- Equity
- Index Tracked
- S&P Healthcare Equipment Select Industry
XHE Summary
XHE is the SPDR S&P Health Care Equipment ETF, which follows the S&P Health Care Equipment Select Industry Index. It focuses on U.S. companies that make medical devices and supplies used in hospitals and clinics. Well-known holdings include Intuitive Surgical and Stryker, along with many smaller, specialized equipment makers. Someone might invest in XHE to tap into the long-term growth of medical technology and to spread their money across many health care equipment companies instead of picking just one stock. A key risk is that it can go up or down with the health care sector and may be more volatile than the broader market.
How much will it cost me?
XHE has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 invested. This cost is a bit higher than the average broad-market index ETF because XHE is a more specialized, sector-focused fund that requires more targeted management.
What would affect this ETF?
XHE could benefit from ongoing medical technology innovation, an aging U.S. population, and steady demand for health care equipment from companies like Intuitive Surgical and Stryker, especially if health care spending and supportive regulations continue. On the negative side, tighter hospital budgets, changes in U.S. health care policy or reimbursement, and higher interest rates that pressure growth-focused health care stocks could weigh on the fund’s performance.
XHE Top 10 Holdings
XHE is a pure play on U.S. medical technology, with health care equipment names steering the ship. High-fliers like Strive, Atricure, and Neogen have been rising steadily, giving the fund a helpful tailwind, while Inspire Medical Systems and Intuitive Surgical are more mixed, with strong businesses but choppier stock action. Alphatec has been lagging and occasionally drags on performance, and Dexcom’s recent softness hasn’t helped. Overall, this is a concentrated bet on innovative medtech rather than broad health care, with North America firmly in the driver’s seat.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ISRG | Intuitive Surgical | 1.98% | $2.99M | $154.56B | -19.11% | 78Outperform |
 ATEC | Alphatec Holdings | 1.88% | $2.84M | $1.68B | -34.44% | 57Neutral |
 RMD | Resmed | 1.78% | $2.69M | $35.27B | -3.24% | 76Outperform |
 HAE | Haemonetics | 1.79% | $2.70M | $5.46B | 134.27% | 70Outperform |
 OMCL | Omnicell | 1.70% | $2.57M | $1.68B | 20.37% | 71Outperform |
 SYK | Stryker | 1.72% | $2.60M | $115.62B | -21.45% | 70Outperform |
 ATRC | Atricure | 1.78% | $2.69M | $3.13B | 68.66% | 71Outperform |
 ENOV | Enovis | 1.72% | $2.60M | $1.24B | -34.45% | 46Neutral |
 BDX | Becton Dickinson | 1.69% | $2.56M | $53.12B | 4.27% | 67Neutral |
 BBNX | Beta Bionics, Inc. | 1.82% | $2.75M | $1.15B | -9.94% | 62Neutral |
XHE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHE, the sentiment is Positive. The current price of 93.25 is above the 20-day moving average (MA) of 90.58, above the 50-day MA of 92.10, and above the 200-day MA of 86.21, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 58.23 is Neutral, neither overbought nor oversold. The STOCH value of 94.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHE.
XHE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| XHE | $93.25 | $96.00(2.95% Upside) | $151.14M | 0.35% | 63Neutral |
 RSPH | $39.35 | $42.25(7.37% Upside) | $976.29M | 0.40% | 71Outperform |
 PJP | $126.36 | $155.32(22.92% Upside) | $558.31M | 0.58% | 70Neutral |
 XPH | $63.96 | $105.79(65.40% Upside) | $438.96M | 0.35% | 57Neutral |
 PBE | $100.74 | $122.44(21.53% Upside) | $431.86M | 0.59% | 70Outperform |
 PINK | $39.96 | $49.43(23.69% Upside) | $325.98M | 0.51% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XHE | SPDR S&P Health Care Equipment ETF | 93.25 | 12.71 | 15.78% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.35 | 9.19 | 30.49% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 126.36 | 32.38 | 34.45% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 63.96 | 15.64 | 32.37% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 100.74 | 29.10 | 40.62% | |
| PINK | Simplify Health Care ETF | 39.96 | 6.90 | 20.87% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.